More than 10 percent — well in excess of the U.S. inflation rate — according to an analysis released Monday by Truveris, a health-care data company that tracks drug prices. The firm analyzes data involving hundreds of millions of payments that public and private insurers, businesses and patients make each year to U.S. pharmacies. The result is an index that measures the average price of prescription drugs, driven by the most commonly prescribed medications.
“We’re in our third year of double-digit [increases],” said A.J. Loiacono, the firm’s chief innovation officer, adding that the increases occurred across virtually every drug category. “Double-digit inflation is concerning. I don’t care if it’s for gas or food; it’s rare.”
Truveris found that over the past year, the price of branded drugs — those still on patent — rose 14.77 percent. Specialty drugs, which often are used to treat complex or rare conditions and tend to carry high price tags, rose 9.21 percent. Even generic drugs, which historically have tended to get cheaper over time, rose 2.93 percent.
Nearly every class of drugs experienced an uptick in prices, Loiacono said, but some conditions saw bigger bumps than others. Drugs that treat the symptoms of menopause, for example, rose nearly 34 percent last year. Those that treat gout: 33 percent. Medications for erectile dysfunction: 20 percent.
Despite the growing public spotlight on the cost of prescription drugs, Monday’s analysis showed that price increases during 2015 were roughly similar to those the year before. In 2014, according to Truveris, Americans saw a 10.9 percent increase in the cost of prescription medications, also across nearly every drug class.
Last month, the federal government calculated that prescription drug spending hit $297.7 billion in 2014 — part of the country's $3 trillion in health spending. That's a jump of more than 12 percent, the largest annual increase in more than a decade. A new generation of specialized drugs and price increases on existing medications helped to drive that spike, and officials have predicted that annual spending on medications will grow 6.3 percent on average through 2024.
The pharmaceutical industry has long maintained that drug costs represent only a fraction of overall health costs in the country, that groundbreaking treatments such as new drugs for hepatitis C will save money over the long term and that innovative medications take many years — and billions of dollars — to develop. In addition, generic drugs account for nearly 90 percent of all U.S. prescriptions.
Shkreli is now fighting securities fraud charges, and he has resigned from the company he was leading when he raised the cost of an antiparasitic drug to $750 from $13.50 per pill. But from the halls of Congress to the presidential campaign trail, the much broader issue of drugs costs in the United States is unlikely to fade in 2016.
Some drug companies seem to recognize that fact and already are doing their best to remain beneath the radar in the coming year.
Loiacono said data from the last quarter of 2015 already shows a slowing in the price increases of many drugs. He expects some of that caution to carry over into 2016.
“They are being sensitive to this issue,” he said of manufacturers. “They are aware a lot of people are watching.”